ALK and non-small cell lung carcinoma: The indications for targeted therapy according to the NCCN Guidelines (Version 3.2023, Non-Small-Cell Lung Cancer) are molecular profiling in biopsies and positive detection of driver oncogenes such as the BRAF V600E mutation, METex14 skipping mutation, EGFR exon 19 deletion or exon 21 L858R, EGFR S768I L861Q and/or G719X, ALK rearrangement, ROS1 rearrangement or RET rearrangements [62].